Vitreoretinal Lymphoma: When ‘Stubborn Uveitis’ Turns Out to Be Something Else
Vitreoretinal Lymphoma at a Glance
Some changes need a call today, not at your next visit. Call your eye doctor the same day if you notice any of these:
- A sudden drop in vision, or sudden loss of vision in one eye.
- A new shower of floaters, or a dark curtain or shadow in your sight.
- Severe eye pain, or a red and painful eye.
- New double vision.
Go to the ER right away for sudden weakness on one side, sudden confusion, sudden trouble speaking, or a seizure. Those signs point to the brain, not just the eye. Most calls like these end in a small change to your care, and a few do not. Being seen fast is what gives your team time to act.
If your inflammation improved on steroids and then came back, and this has happened more than once, your doctor is right to look again. Vitreous and subretinal lesions in vitreoretinal lymphoma typically shrink after steroids are started and then recur or progress, which is exactly why it masquerades as uveitis1. That pattern is a clue, not a verdict. Most people whose uveitis relapses do not have lymphoma. Testing for it is how the question gets settled rather than carried from visit to visit.
It is a cancer of one kind of white blood cell that has set up inside the eye. Primary vitreoretinal lymphoma is a high-grade diffuse large B-cell lymphoma of the retina and vitreous (vitreous: the clear gel filling the eye) and is a form of primary central nervous system lymphoma1. That last part explains why an eye diagnosis brings in a brain scan and a cancer team. It is not an infection, and it is not something you caught or caused.
Expect the pace to change once lymphoma is on the list. Usually a vitreous sample is arranged, brain imaging is booked, and a cancer specialist joins your care. An expert consensus panel recommends that systemic steroids (the tablets or infusions, rather than drops) be discontinued at least 2 weeks before that surgery, so the sample is easier to read2. Whether that suits your eye is a judgement your team makes with you. Do not stop steroid drops or tablets on your own, because stopping the wrong one at the wrong time causes its own problems. Ask your doctor which ones to pause and when.
What Vitreoretinal Lymphoma Is
Doctors group this with lymphoma of the central nervous system rather than with lymphoma elsewhere in the body, because the eye and the brain share the same immune territory. About one third of people have central nervous system disease already at presentation3. That is why the workup looks beyond the eye from the very beginning. It also means an eye doctor is rarely the only specialist involved for long.
This is a genuinely uncommon diagnosis. The age-adjusted incidence in the United States is about 0.23 per million people, the median age at diagnosis is over 63 years, more than 20 of every 100 patients are older than 80, and the rate in people aged 60 and over is nearly 18 times that of younger people3. The peak falls between 50 and 70 years of age4. Rarity is part of why the diagnosis is often delayed, and it is also why referral to a center that sees these cases matters.
One eye is often affected first, and the other tends to follow. Between 80 and 90 of every 100 people develop disease in both eyes, although the first presentation may be one-sided1, and 67 of every 100 already have both eyes involved when they are first assessed5. If your second eye is currently clear, it will still be examined at every visit. That is monitoring rather than an expectation of bad news.
Why It Looks Like Uveitis for So Long
The complaints are almost identical to those of ordinary posterior uveitis, which is the heart of the problem. Presentation is typically floaters and painless vision loss, without redness or light sensitivity, together with multifocal creamy white lesions in the outer retina4. Floaters and painless vision loss are the usual symptoms3. Nothing about how it feels tells the two apart. The distinction is made on the exam findings and on what a laboratory finds in a sample of the vitreous.
Steroids calm the eye at first, which looks like confirmation that the diagnosis was inflammation. The lesions typically regress after steroids are started and then recur or progress after that initial response1. Systemic steroids should not be used as the only treatment, because their effect here is limited4. If your treatment has followed a cycle of improvement then relapse, you have not been mismanaged. You have run into the single most deceptive feature of this disease.
Certain mismatches between how the eye looks and how it behaves push lymphoma up the list. The features that raise suspicion are better vision than the amount of inflammation would predict, minimal flare in the front of the eye, dense vitreous cells, and the absence of posterior synechiae or cystoid macular edema4.
| Finding | More typical of uveitis | Raises suspicion of lymphoma |
|---|---|---|
| Vision versus inflammation | Vision drops in step with inflammation | Vision better than expected4 |
| Front-of-eye flare | Often marked | Minimal4 |
| Response to steroids | Sustained improvement | Improves, then recurs1 |
What Causes It and Who Is at Higher Risk
There is no lifestyle exposure, diet or eye habit that has been shown to bring this on, and nothing you did explains it. What is known is the biology of the cells involved. It is a high-grade diffuse large B-cell lymphoma arising in the retina and vitreous1, and the MYD88 L265P gene change is found in most samples that are tested, although the reported rate varies with the study and the testing method, from about 60 to 80 of every 100 cases in one review to between 74 and 100 of every 100 samples in individual small series67. That is a change found in the tumor cells themselves rather than one inherited from a parent. A negative result does not settle the question on its own, which is why it is read alongside the other tests.
Age is by far the strongest factor. The incidence in people aged 60 and over is nearly 18 times that in younger people, and the median age at diagnosis is over 633. Your team will ask about immune-suppressing medicines and other health conditions as part of the workup. Most people who develop this have no identifiable risk factor beyond their age, which is unsatisfying and also true.
Symptoms in the Eye and Beyond
The eye symptoms are quiet rather than dramatic. Floaters and painless vision loss are the typical complaints, without the redness or light sensitivity that many people associate with eye inflammation4. Vision may be hazy, as though looking through smoke, and it can fluctuate. Because it is painless and gradual, people often adapt to it before seeking help. That adaptation is normal and is not a reason to feel you left it too late.
The retinal picture is where the suspicion usually starts. Findings can include inflammation in the front of the eye with keratic precipitates, vitreous opacities, and yellow-white lesions beneath the retina that enlarge and merge, sometimes with a leopard-spot pigment pattern, plus vasculitis with retinal hemorrhages and optic disc involvement1. You may hear these described during your exam. Ask your doctor to show you the photographs, because seeing them makes the reasoning far easier to follow.
These matter because of where this lymphoma lives. Neurological features reported include changes in behavior or thinking in 25 to 30 of every 100 people, weakness on one side, headache or difficulty with speech in 10 to 15 of every 100, seizures in about 5 of every 100, and unsteadiness in about 4 of every 1003. Tell your team promptly about any of these, and treat sudden weakness, sudden confusion, sudden trouble speaking or a seizure as a reason to seek emergency care that day.
How Vitreoretinal Lymphoma Is Diagnosed
A sample of the gel inside the eye is the central test. The reference standard is an undiluted vitrectomy specimen of about 0.5 to 1 mL taken at a low cut rate1. An expert consensus panel and a clinical review chapter give the same interval: steroids discontinued for at least 2 weeks before the biopsy, because steroids thin out the very cells the laboratory is looking for26. The consensus wording is specific to systemic steroids2, so ask which of your own medicines it covers. Vitrectomy is done in an operating room, usually under local anesthesia. Your eye will be sore and blurry for some days afterward, and your surgeon will explain the specific restrictions for your case.
Several tests are run together, because no single one settles it. Cytology is the reference test but is sufficient in only 48 of every 100 cases, so it is combined with an IL-10 to IL-6 ratio above 1, testing for the MYD88 L265P mutation, reported in up to 87 of every 100 specimens, and flow cytometry to confirm that the cells come from a single clone1. A first sample that does not give an answer is common, and a repeat biopsy is sometimes needed rather than a failure of the first one.
The eye result is only part of the staging. MRI of the brain should be performed for everyone with suspected primary vitreoretinal lymphoma, and lumbar puncture is used to look for spread to the fluid around the brain and spinal cord1. A lumbar puncture takes a small sample of that fluid through a needle in the lower back, with local anesthetic. These tests decide whether treatment is aimed only at the eye or at the whole central nervous system, so they change the plan rather than just documenting it.
How Vitreoretinal Lymphoma Is Treated
Local treatment puts the drug where the disease is. Injections of methotrexate into the eye have been reported to clear intraocular lesions in up to about 98 of every 100 eyes, compared with about 65 of every 100 for rituximab, and a 2024 optimized protocol lowered the rate of corneal surface problems from 20 to 30 of every 100 down to about 10 of every 1001. These eye injections are used off-label for this condition, meaning they are not FDA-approved for this specific use. Clearing the eye is not the same as treating the whole disease, which is why systemic treatment is usually discussed alongside it.
Because the eye and brain are one compartment here, most plans reach beyond the eye. High-dose methotrexate-based systemic chemotherapy is the standard approach, increasingly combined with rituximab, while external beam radiation has largely been replaced by injections into the eye because of its toxicity1. In one prospective study using combined chemotherapy with reduced-dose whole-brain radiotherapy, progression to the central nervous system at 4 years was 10.0 of every 100 and 4-year progression-free survival was 72.7 of every 1003. Your own regimen depends on your staging, age and other health conditions.
Follow-up is long, and that is deliberate rather than pessimistic. There is a high risk of recurrent disease, so people need to be followed indefinitely1. Expect repeated eye examinations, periodic brain imaging, and blood tests, with the interval stretching out over time if things stay quiet. Keep a single folder of your scan reports and pathology results. Care is often shared between an eye center and a cancer center, and you are the one person who attends both.
Risks, Outlook and Living With the Diagnosis
This is the number most people want, and it comes with a wide range. Across 25 studies totaling 371 people, 169 of them, about 46 of every 100, eventually developed central nervous system disease, with rates between studies ranging from 0 to 86 of every 100, and the mean time to that involvement falling between 8 and 34 months5. Bilateral and one-sided disease did not differ significantly in that risk (pooled relative risk 1.12, 95% confidence interval 0.89 to 1.41)5. Regular brain imaging exists to catch that change early.
The published numbers are genuinely inconsistent, and you deserve to know that rather than be handed one figure. Reported mortality has varied from 9 to 81 of every 100 across follow-up periods of 12 to 49 months5. Reported survival for primary central nervous system lymphoma has improved markedly compared with the era of radiation alone, when it was around a year1. None of those figures forecasts your own course. Your oncologist can tell you which studies resemble your situation.
Many people arrive here after months or years of being treated for something else, and the anger about that is reasonable. It is also worth knowing that the delay is built into the disease rather than into your care. Ask for your full record, including the biopsy report, so you can follow the reasoning. Bring one person to the appointments where decisions are made. Ask your cancer center what psychological and practical support they offer, because most have it and few advertise it.
When to Call Your Doctor and Who You Will See
Contact your team the same day for a sudden drop in vision, a new dense shower of floaters, or new eye pain. Seek emergency care for sudden weakness on one side, sudden confusion, sudden trouble speaking or a seizure. Those neurological features are recognized presentations of central nervous system involvement, with behavior or thinking changes in 25 to 30 of every 100 people and seizures in about 5 of every 1003. Most calls turn out to be something manageable. Making the call is still the right move.
Expect several specialties rather than one doctor. A retina specialist or uveitis specialist manages the eye and performs the vitrectomy. An ocular oncologist may be involved where one is available. A hematologist or neuro-oncologist runs the systemic treatment, and a neurologist joins if the brain is affected. Ask who is coordinating between the eye center and the cancer center, and ask for that person's contact details in writing.
Common Questions About Vitreoretinal Lymphoma
Not in the sense of a mistake. This lymphoma closely resembles uveitic conditions and its lesions regress after steroids are started before recurring, which is precisely what causes the diagnostic delay1. It is uncommon, and the early picture is indistinguishable from inflammation without a vitreous sample. What matters now is that the question has been asked and can be answered with testing rather than left open.
Because the eye and the central nervous system are one compartment for this disease. MRI of the brain should be performed for everyone with suspected primary vitreoretinal lymphoma, and lumbar puncture is used to check the fluid around the brain and spinal cord1. About one third of people already have central nervous system disease when they are first diagnosed3. Finding that early changes the treatment plan, which is the point of doing it up front.
It is the central test, and it is combined with laboratory work on the sample. The reference standard is an undiluted vitrectomy specimen, with cytology sufficient in only 48 of every 100 cases, so it is supported by the IL-10 to IL-6 ratio, MYD88 mutation testing and flow cytometry1. Some centers can test aqueous fluid from the front of the eye as well. Ask your surgeon which tests your sample will be sent for, since not every laboratory runs all of them.
Because steroids reduce the very cells the laboratory is looking for. An expert consensus panel recommends stopping systemic steroids at least 2 weeks before the surgery2, and your surgeon decides whether your eye can wait that long. Pausing them may make the eye feel worse in the meantime, which is uncomfortable and temporary. Never stop a steroid tablet on your own schedule, because some need tapering. Ask your team exactly which medicines to hold and from which date.
Not necessarily, and the eye disease often responds to treatment. Injections of methotrexate into the eye have cleared intraocular lesions in up to about 98 of every 100 eyes in reported series1. Vision depends on how much damage the retina and optic nerve have already sustained, and on how the disease behaves over time. No one can promise you a particular level of sight, and your retina specialist can track it visit by visit with imaging.
It is the same family of disease in a different place, and the location changes everything about treatment. Primary vitreoretinal lymphoma is a form of primary central nervous system lymphoma, a high-grade diffuse large B-cell lymphoma1. Drugs have to reach past the barrier that protects the brain and the eye, which is why high-dose methotrexate is used rather than the regimens given for lymphoma in lymph nodes.
More Questions About Treatment, Risk and Follow-Up
Substantial, and reported over a wide range. Across 25 studies totaling 371 people, about 46 of every 100 eventually developed central nervous system disease, with study-level rates from 0 to 86 of every 100 and a mean time to involvement of 8 to 34 months5. Other series report 42 to 92 of every 100 progressing within an average of 8 to 29 months3. That variation reflects differing populations and follow-up, which is why your own scans matter more than any published range.
That is a decision for your team, and the second eye is watched closely either way. Between 80 and 90 of every 100 people eventually have both eyes involved, even when the first presentation is one-sided1. Whether one or both eyes are involved did not significantly change the risk of central nervous system progression in a meta-analysis of 25 studies5. Ask what the plan is for the unaffected eye and how often it will be examined.
Indefinitely, and the intervals usually lengthen if things stay stable. There is a high risk of recurrent disease, so patients need to be followed indefinitely1. In practice that means eye examinations, brain imaging and blood tests on a schedule your team sets. Keep every report. If you move or change hospitals, a complete record is what lets a new team pick up without repeating tests you have already had.
It is reasonable, and it is common in rare cancers. The condition is rare, with an age-adjusted incidence of about 0.23 per million people in the United States3, so experience is concentrated in a small number of centers. Ask that your vitreous pathology and your MRI be reviewed rather than repeated where possible. A second opinion on a rare diagnosis is a normal part of care, not a comment on your current team.
- What did my vitreous sample show, and which tests were run on it?
- Was the MYD88 mutation tested, and what was the IL-10 to IL-6 ratio?
- What did my brain MRI and lumbar puncture show?
- Is my treatment aimed at the eye only, or at the whole central nervous system?
- Which of my medicines should I pause before any procedure, and when?
- How often will my other eye be examined?
- How often will I have brain imaging, and for how long?
- Which symptoms should send me to an emergency department rather than your clinic?
- Who coordinates between the eye service and the cancer service?
- EyeWiki, American Academy of Ophthalmology (2025). Primary Vitreoretinal Lymphoma (EyeWiki).
- Ocular Immunology and Inflammation 29(3):507-520; two-round Delphi consensus of 28 international experts (PMID 34009095) (2021). Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma.
- Blood Science (PubMed Central PMC12047895), narrative review of published PVRL series and registry data (2025). Primary vitreoretinal lymphoma: diagnosis, treatment, and prognosis, a review of current knowledge and future directions.
- Retina Today, clinical review (2025). Neoplastic Masqueraders of Uveitis.
- Cancers, systematic review and meta-analysis of 25 studies totalling 371 cases (2022). Central Nervous System Progression in Primary Vitreoretinal Lymphoma with Bilateral and Unilateral Involvement: A Systematic Review and Meta-Analysis.
- StatPearls, NCBI Bookshelf NBK576390; peer-reviewed clinical review chapter, updated 19 June 2026 (2026). Primary Intraocular Lymphoma (StatPearls).
- Eye and Vision (London), PMC12105337; clinical guideline of the Ocular Immunology Group, Chinese Medical Association Ophthalmology Branch (2025). Clinical guidelines for the diagnosis and treatment of vitreoretinal lymphoma in Chinese patients (2024).